| Literature DB >> 33586770 |
Yuqi Zhou1, Colby R Maldini1, Julie Jadlowsky1, James L Riley1.
Abstract
HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.Entities:
Keywords: T-cell exhaustion; T-cell receptor; antiretroviral therapy; chimeric antigen receptor; ex vivo T-cell expansion; human-immunodeficiency-virus; latency reversing agent
Mesh:
Year: 2021 PMID: 33586770 PMCID: PMC7883023 DOI: 10.1093/infdis/jiaa223
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226